The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Stocks•4 June 2026•

2 min read

Spectral Medical Reports Positive 12-Month Data for Tigris Trial

Key Facts

1The Tigris trial showed 12-month mortality was 52.8% with PMX vs. 66.7% with standard of care alone.

2The study achieved a 95.9% probability of benefit for PMX based on Tigris data alone.

Amid the ongoing search for innovative medical solutions for critical care, Spectral Medical and Vantive announced positive 12-month follow-up results from the Tigris clinical trial. According to reports, the trial showed that 12-month mortality decreased to 52.8% using PMX technology, compared to 66.7% for patients receiving standard of care alone. The study achieved a 95.9% probability of benefit for PMX based on Tigris data, bolstering hopes for the efficacy of the PMX cartridge in treating endotoxemic septic shock.

These results arrive at a critical juncture for the biotech sector, as micro-cap firms strive to present robust clinical data to support regulatory pathways. Compared to medical device giants like Baxter International (which owns Vantive), the success of the Tigris trial represents a strategic step toward commercializing advanced blood purification technologies. Per market data, an absolute risk reduction in mortality of over 13% is considered a significant clinical milestone in treating septic shock conditions that currently face limited therapeutic options.

Investors should monitor upcoming steps regarding the submission of this data to regulatory bodies for final approvals. Looking at the economic calendar, the market awaits US Consumer Confidence data and speeches from Fed officials on May 29, 2026, which may influence investor sentiment in the high-risk healthcare sector. The outlook remains cautiously bullish pending independent validation of the results and the completion of the product's commercial roadmap.